Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Grant

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|September 22, 2005
Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) proteinJane E Armes, Rohan Lourie, Melanie de Silva, et al.
Journal of Gynecologic Oncology|October 30, 2013
Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG studyPrunella Blinman, Corona Gainford, Mark Donoghoe, et al.
Gynecologic Oncology|December 27, 2021
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)Vanessa L Beesley, Tanya L Ross, Madeleine T King, et al.
Journal of Gynecologic Oncology|July 23, 2019
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey Sei Kok, Philip Beale, Rachel L O'Connell, et al.
The American Journal of Clinical Nutrition|May 15, 2015
Circulating 25-hydroxyvitamin D and survival in women with ovarian cancerPenelope M Webb, Anna de Fazio, Melinda M Protani, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|May 3, 2021
Possible high-grade squamous intraepithelial lesion (pHSIL) in the new cervical screening paradigm: The outcomes and the role of clinicopathological reviewMonica Francesca Giannini McGauran, Adam Bernard Pendlebury, Richard John Hiscock, et al.
Blood Advances|December 6, 2025
Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stressChristina Mayerhofer, Eve Crompton, Ernst Mayerhofer, et al.
Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.
Internal Medicine Journal|December 6, 2018
Cluster of invasive Mycobacteria chimaera infections following cardiac surgery demonstrating novel clinical features and risks of aortic valve replacementKristen Overton, Vidthyia Mennon, Nomvuyo Mothobi, et al.
Oncotarget|October 15, 2017
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome lociDylan M Glubb, Sharon E Johnatty, Michael C J Quinn, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|September 22, 2005
Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) proteinJane E Armes, Rohan Lourie, Melanie de Silva, et al.
Journal of Gynecologic Oncology|October 30, 2013
Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG studyPrunella Blinman, Corona Gainford, Mark Donoghoe, et al.
Gynecologic Oncology|December 27, 2021
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)Vanessa L Beesley, Tanya L Ross, Madeleine T King, et al.
Journal of Gynecologic Oncology|July 23, 2019
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey Sei Kok, Philip Beale, Rachel L O'Connell, et al.
The American Journal of Clinical Nutrition|May 15, 2015
Circulating 25-hydroxyvitamin D and survival in women with ovarian cancerPenelope M Webb, Anna de Fazio, Melinda M Protani, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|May 3, 2021
Possible high-grade squamous intraepithelial lesion (pHSIL) in the new cervical screening paradigm: The outcomes and the role of clinicopathological reviewMonica Francesca Giannini McGauran, Adam Bernard Pendlebury, Richard John Hiscock, et al.
Blood Advances|December 6, 2025
Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stressChristina Mayerhofer, Eve Crompton, Ernst Mayerhofer, et al.
Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.
Internal Medicine Journal|December 6, 2018
Cluster of invasive Mycobacteria chimaera infections following cardiac surgery demonstrating novel clinical features and risks of aortic valve replacementKristen Overton, Vidthyia Mennon, Nomvuyo Mothobi, et al.
Oncotarget|October 15, 2017
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome lociDylan M Glubb, Sharon E Johnatty, Michael C J Quinn, et al.
Pageof 7